JP2014533271A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2014533271A5 JP2014533271A5 JP2014541225A JP2014541225A JP2014533271A5 JP 2014533271 A5 JP2014533271 A5 JP 2014533271A5 JP 2014541225 A JP2014541225 A JP 2014541225A JP 2014541225 A JP2014541225 A JP 2014541225A JP 2014533271 A5 JP2014533271 A5 JP 2014533271A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- composition according
- imidazol
- ylmethyl
- dermatitis
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000008194 pharmaceutical composition Substances 0.000 claims 20
- LBUJPTNKIBCYBY-UHFFFAOYSA-N 1,2,3,4-tetrahydroquinoline Chemical compound C1=CC=C2CCCNC2=C1 LBUJPTNKIBCYBY-UHFFFAOYSA-N 0.000 claims 8
- 206010015150 Erythema Diseases 0.000 claims 7
- 201000004700 rosacea Diseases 0.000 claims 7
- 241001303601 Rosacea Species 0.000 claims 6
- 125000003287 1H-imidazol-4-ylmethyl group Chemical group [H]N1C([H])=NC(C([H])([H])[*])=C1[H] 0.000 claims 5
- 208000003251 Pruritus Diseases 0.000 claims 4
- 231100000321 erythema Toxicity 0.000 claims 4
- 201000004624 Dermatitis Diseases 0.000 claims 3
- 201000008937 atopic dermatitis Diseases 0.000 claims 3
- 239000004744 fabric Substances 0.000 claims 3
- 230000001815 facial effect Effects 0.000 claims 3
- 230000003287 optical effect Effects 0.000 claims 3
- 239000005022 packaging material Substances 0.000 claims 3
- 239000000825 pharmaceutical preparation Substances 0.000 claims 3
- 229940127557 pharmaceutical product Drugs 0.000 claims 3
- SIDBSMXMBWXFQV-UHFFFAOYSA-N 7-(1h-imidazol-5-ylmethyl)-5,6,7,8-tetrahydroquinoline Chemical compound C1CC2=CC=CN=C2CC1CC1=CNC=N1 SIDBSMXMBWXFQV-UHFFFAOYSA-N 0.000 claims 2
- 208000002874 Acne Vulgaris Diseases 0.000 claims 2
- 206010051625 Conjunctival hyperaemia Diseases 0.000 claims 2
- 206010012438 Dermatitis atopic Diseases 0.000 claims 2
- 206010016825 Flushing Diseases 0.000 claims 2
- 201000004681 Psoriasis Diseases 0.000 claims 2
- 201000002154 Pterygium Diseases 0.000 claims 2
- 206010042496 Sunburn Diseases 0.000 claims 2
- 206010043189 Telangiectasia Diseases 0.000 claims 2
- 206010000496 acne Diseases 0.000 claims 2
- 208000010668 atopic eczema Diseases 0.000 claims 2
- 230000010339 dilation Effects 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 239000000839 emulsion Substances 0.000 claims 2
- 238000011010 flushing procedure Methods 0.000 claims 2
- 230000007803 itching Effects 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- 239000000203 mixture Substances 0.000 claims 2
- 150000003839 salts Chemical class 0.000 claims 2
- 230000008961 swelling Effects 0.000 claims 2
- 208000009056 telangiectasis Diseases 0.000 claims 2
- SIDBSMXMBWXFQV-SNVBAGLBSA-N (7r)-7-(1h-imidazol-5-ylmethyl)-5,6,7,8-tetrahydroquinoline Chemical compound C([C@@H]1CC2=NC=CC=C2CC1)C1=CNC=N1 SIDBSMXMBWXFQV-SNVBAGLBSA-N 0.000 claims 1
- 206010004146 Basal cell carcinoma Diseases 0.000 claims 1
- 206010012434 Dermatitis allergic Diseases 0.000 claims 1
- 206010012442 Dermatitis contact Diseases 0.000 claims 1
- 206010012456 Dermatitis exfoliative generalised Diseases 0.000 claims 1
- 206010015226 Erythema nodosum Diseases 0.000 claims 1
- 208000010201 Exanthema Diseases 0.000 claims 1
- 206010016717 Fistula Diseases 0.000 claims 1
- 206010016936 Folliculitis Diseases 0.000 claims 1
- 206010018691 Granuloma Diseases 0.000 claims 1
- 208000006877 Insect Bites and Stings Diseases 0.000 claims 1
- 206010072139 Ocular rosacea Diseases 0.000 claims 1
- 208000009675 Perioral Dermatitis Diseases 0.000 claims 1
- 206010051246 Photodermatosis Diseases 0.000 claims 1
- 206010037549 Purpura Diseases 0.000 claims 1
- 241001672981 Purpura Species 0.000 claims 1
- 206010039793 Seborrhoeic dermatitis Diseases 0.000 claims 1
- 206010041955 Stasis dermatitis Diseases 0.000 claims 1
- 206010042674 Swelling Diseases 0.000 claims 1
- 208000024780 Urticaria Diseases 0.000 claims 1
- 206010046996 Varicose vein Diseases 0.000 claims 1
- 208000016807 X-linked intellectual disability-macrocephaly-macroorchidism syndrome Diseases 0.000 claims 1
- 208000009621 actinic keratosis Diseases 0.000 claims 1
- 239000000443 aerosol Substances 0.000 claims 1
- 208000003373 basosquamous carcinoma Diseases 0.000 claims 1
- 230000001684 chronic effect Effects 0.000 claims 1
- 208000010247 contact dermatitis Diseases 0.000 claims 1
- 239000002537 cosmetic Substances 0.000 claims 1
- 239000006071 cream Substances 0.000 claims 1
- 239000006185 dispersion Substances 0.000 claims 1
- 206010015037 epilepsy Diseases 0.000 claims 1
- 201000005884 exanthem Diseases 0.000 claims 1
- 230000003890 fistula Effects 0.000 claims 1
- 239000006260 foam Substances 0.000 claims 1
- 238000009472 formulation Methods 0.000 claims 1
- 239000000499 gel Substances 0.000 claims 1
- 238000002347 injection Methods 0.000 claims 1
- 239000007924 injection Substances 0.000 claims 1
- 230000007794 irritation Effects 0.000 claims 1
- 239000007788 liquid Substances 0.000 claims 1
- 239000006210 lotion Substances 0.000 claims 1
- 230000009245 menopause Effects 0.000 claims 1
- 239000004530 micro-emulsion Substances 0.000 claims 1
- 239000003094 microcapsule Substances 0.000 claims 1
- 239000011859 microparticle Substances 0.000 claims 1
- 239000002674 ointment Substances 0.000 claims 1
- 230000008845 photoaging Effects 0.000 claims 1
- 238000002360 preparation method Methods 0.000 claims 1
- 230000001107 psychogenic effect Effects 0.000 claims 1
- 206010037844 rash Diseases 0.000 claims 1
- 238000002271 resection Methods 0.000 claims 1
- 208000008742 seborrheic dermatitis Diseases 0.000 claims 1
- 239000000243 solution Substances 0.000 claims 1
- 239000007921 spray Substances 0.000 claims 1
- 238000007920 subcutaneous administration Methods 0.000 claims 1
- 239000000725 suspension Substances 0.000 claims 1
- 208000024891 symptom Diseases 0.000 claims 1
- 208000011580 syndromic disease Diseases 0.000 claims 1
- 230000002381 testicular Effects 0.000 claims 1
- 230000000699 topical effect Effects 0.000 claims 1
- 208000027185 varicose disease Diseases 0.000 claims 1
- 230000024883 vasodilation Effects 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161558104P | 2011-11-10 | 2011-11-10 | |
| US61/558,104 | 2011-11-10 | ||
| PCT/US2012/064075 WO2013070861A1 (en) | 2011-11-10 | 2012-11-08 | Pharmaceutical compositions comprising 7-(1h-imidazol-4-ylmethyl)-5,6,7,8-tetrahydro-quinoline for treating skin diseases and conditions |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017092572A Division JP6526737B2 (ja) | 2011-11-10 | 2017-05-08 | ７−（１ｈ−イミダゾール−４−イルメチル）−５，６，７，８−テトラヒドロキノリンを含む肌の疾患および状態を治療するための医薬組成物 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2014533271A JP2014533271A (ja) | 2014-12-11 |
| JP2014533271A5 true JP2014533271A5 (enExample) | 2016-01-07 |
| JP6359456B2 JP6359456B2 (ja) | 2018-07-18 |
Family
ID=47178364
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014541225A Active JP6359456B2 (ja) | 2011-11-10 | 2012-11-08 | ７−（１ｈ−イミダゾール−４−イルメチル）−５，６，７，８−テトラヒドロキノリンを含む肌の疾患および状態を治療するための医薬組成物 |
| JP2017092572A Active JP6526737B2 (ja) | 2011-11-10 | 2017-05-08 | ７−（１ｈ−イミダゾール−４−イルメチル）−５，６，７，８−テトラヒドロキノリンを含む肌の疾患および状態を治療するための医薬組成物 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017092572A Active JP6526737B2 (ja) | 2011-11-10 | 2017-05-08 | ７−（１ｈ−イミダゾール−４−イルメチル）−５，６，７，８−テトラヒドロキノリンを含む肌の疾患および状態を治療するための医薬組成物 |
Country Status (22)
| Country | Link |
|---|---|
| US (4) | US20130123303A1 (enExample) |
| EP (3) | EP2776034B1 (enExample) |
| JP (2) | JP6359456B2 (enExample) |
| KR (1) | KR102004563B1 (enExample) |
| CN (1) | CN104136029A (enExample) |
| AR (1) | AR088845A1 (enExample) |
| AU (2) | AU2012335803B2 (enExample) |
| BR (1) | BR112014011336A2 (enExample) |
| CA (1) | CA2855005C (enExample) |
| CL (1) | CL2014001242A1 (enExample) |
| DK (1) | DK2776034T3 (enExample) |
| ES (1) | ES2635421T3 (enExample) |
| IL (3) | IL232483B (enExample) |
| MX (1) | MX350662B (enExample) |
| MY (1) | MY182553A (enExample) |
| PH (1) | PH12014501051A1 (enExample) |
| RU (2) | RU2630978C2 (enExample) |
| SG (3) | SG11201402246RA (enExample) |
| TW (3) | TW202014189A (enExample) |
| UA (1) | UA109359C2 (enExample) |
| WO (1) | WO2013070861A1 (enExample) |
| ZA (1) | ZA201403396B (enExample) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9283217B2 (en) | 2011-11-10 | 2016-03-15 | Allergan, Inc. | Pharmaceutical compositions comprising 7-(1 H-imidazol-4-ylmethyl)-5,6,7,8-tetrahydro-quinoline for treating skin diseases and conditions |
| AU2014262960A1 (en) * | 2013-05-06 | 2015-11-26 | Allergan, Inc. | Alpha adrenergic agonists for the treatment of tissue trauma |
| FR3061434B1 (fr) * | 2017-01-04 | 2019-07-12 | Pierre Fabre Dermo-Cosmetique | Composition cosmetique comprenant une association d'huile de pongamia et de pentylene glycol 4-t-butylcyclohexanol pour lutter contre la rosacee |
| RU2727695C1 (ru) * | 2020-02-13 | 2020-07-22 | Мурад Умарович Магомедов | Способ комплексного лечения ринофимы |
Family Cites Families (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE319456T1 (de) * | 1998-05-08 | 2006-03-15 | Univ Miami | Verwendung von tetracyclinen zur behandlung von störungen der meibomschen drüsen |
| WO2004073708A1 (en) * | 1998-12-17 | 2004-09-02 | Dean Thomas R | Brinzolamide and brimonidine for treating ocular conditions |
| US20010049369A1 (en) * | 2000-02-10 | 2001-12-06 | Jablonski Monica M. | Brimonidine compositions and methods for retinal degeneration |
| US6468989B1 (en) | 2000-07-13 | 2002-10-22 | Dow Pharmaceutical Sciences | Gel compositions containing metronidazole |
| US6387383B1 (en) | 2000-08-03 | 2002-05-14 | Dow Pharmaceutical Sciences | Topical low-viscosity gel composition |
| US20020198209A1 (en) | 2001-05-03 | 2002-12-26 | Allergan Sales Inc. | Compositions having enhanced pharmacokinetic characteristics |
| US6680062B2 (en) | 2001-10-05 | 2004-01-20 | Color Access, Inc. | Anti-irritating rosacea treatment |
| US7030149B2 (en) * | 2002-04-19 | 2006-04-18 | Allergan, Inc. | Combination of brimonidine timolol for topical ophthalmic use |
| US20040146539A1 (en) * | 2003-01-24 | 2004-07-29 | Gupta Shyam K. | Topical Nutraceutical Compositions with Selective Body Slimming and Tone Firming Antiaging Benefits |
| US7439241B2 (en) * | 2003-05-27 | 2008-10-21 | Galderma Laboratories, Inc. | Compounds, formulations, and methods for treating or preventing rosacea |
| US20050020600A1 (en) * | 2003-07-23 | 2005-01-27 | Scherer Warren J. | Methods of treating cutaneous flushing using selective alpha-2-adrenergic receptor agonists |
| ZA200604403B (en) * | 2003-11-20 | 2007-09-26 | Othera Pharmaceuticals Inc | Amelioration of macular degeneration and other ophthalmic diseases |
| US7812049B2 (en) | 2004-01-22 | 2010-10-12 | Vicept Therapeutics, Inc. | Method and therapeutic/cosmetic topical compositions for the treatment of rosacea and skin erythema using α1-adrenoceptor agonists |
| CA2567401C (en) * | 2004-05-25 | 2013-11-12 | Sansrosa Pharmaceutical Development, Inc. | Compounds, formulations, and methods for treating or preventing inflammatory skin disorders |
| US20070203144A1 (en) * | 2006-01-17 | 2007-08-30 | Allergan, Inc. | Use of Memantine and Brimonidine to Attenuate Vitreoretinal Vascular Endothelial Growth Factor (VEGF) Protein Levels in Animals |
| US7323477B2 (en) * | 2006-02-02 | 2008-01-29 | Allergan, Inc. | 7-((1H-imidazol-4-yl)methyl)-5,6,7,8-tetrahydroquinoline |
| RU2321399C1 (ru) * | 2006-06-01 | 2008-04-10 | Федеральное государственное учреждение "Нижегородский научно-исследовательский кожно-венерологический институт Федерального агентства по здравоохранению и социальному развитию" | Способ лечения больных розацеа |
| WO2008124151A2 (en) * | 2007-04-09 | 2008-10-16 | Avicena Group, Inc. | Use of creatine compounds for the treatment of eye disorders |
| US20090061020A1 (en) * | 2007-08-31 | 2009-03-05 | Theobald Klaus P | Brimonidine Compositions for Treating Erythema |
| WO2009052073A2 (en) * | 2007-10-18 | 2009-04-23 | Allergan, Inc. | Method of treating sensorimotor disorders with alpha-2 adrenergic receptor agonists |
| CA2732521C (en) * | 2008-08-01 | 2017-11-07 | Alpha Synergy Development, Inc. | Vasoconstriction compositions and methods of use |
| US20100203165A1 (en) * | 2008-08-01 | 2010-08-12 | Gerald Horn | Compositions and methods for treatment of disorders or conditions of the eye |
| FR2942138A1 (fr) | 2009-02-16 | 2010-08-20 | Galderma Res & Dev | Association de composes pour le traitement ou la prevention des affections dermatologiques |
| EP2493309A4 (en) * | 2009-10-26 | 2013-05-01 | Galderma Pharma Sa | METHODS OF TREATING OR PREVENTING ACUTE ERYTHEMA |
| US8394800B2 (en) * | 2009-11-19 | 2013-03-12 | Galderma Laboratories, L.P. | Method for treating psoriasis |
| RU2535008C2 (ru) * | 2010-03-26 | 2014-12-10 | Галдерма Ресерч Энд Девелопмент | Улучшенные способы и композиции для безопасного и эффективного лечения телеангиэктазии |
| MX2012010824A (es) * | 2010-03-26 | 2012-10-10 | Galderma Res & Dev | Metodos y composiciones mejoradas para tratamiento seguro y efectivo del eritema. |
| US20130190317A1 (en) * | 2010-08-06 | 2013-07-25 | Galderma Research & Development Snc | Combination of compounds for treating or preventing skin diseases |
-
2012
- 2012-08-11 UA UAA201406109A patent/UA109359C2/ru unknown
- 2012-11-08 KR KR1020147015533A patent/KR102004563B1/ko not_active Expired - Fee Related
- 2012-11-08 BR BR112014011336A patent/BR112014011336A2/pt not_active Application Discontinuation
- 2012-11-08 WO PCT/US2012/064075 patent/WO2013070861A1/en not_active Ceased
- 2012-11-08 DK DK12784857.0T patent/DK2776034T3/en active
- 2012-11-08 SG SG11201402246RA patent/SG11201402246RA/en unknown
- 2012-11-08 EP EP12784857.0A patent/EP2776034B1/en active Active
- 2012-11-08 SG SG10201609145PA patent/SG10201609145PA/en unknown
- 2012-11-08 RU RU2014122758A patent/RU2630978C2/ru active
- 2012-11-08 CA CA2855005A patent/CA2855005C/en active Active
- 2012-11-08 PH PH1/2014/501051A patent/PH12014501051A1/en unknown
- 2012-11-08 JP JP2014541225A patent/JP6359456B2/ja active Active
- 2012-11-08 MX MX2014005640A patent/MX350662B/es active IP Right Grant
- 2012-11-08 SG SG10201809506TA patent/SG10201809506TA/en unknown
- 2012-11-08 RU RU2017131492A patent/RU2667645C1/ru active
- 2012-11-08 MY MYPI2014001376A patent/MY182553A/en unknown
- 2012-11-08 EP EP17156230.9A patent/EP3184110B1/en active Active
- 2012-11-08 CN CN201280065945.0A patent/CN104136029A/zh active Pending
- 2012-11-08 AU AU2012335803A patent/AU2012335803B2/en not_active Ceased
- 2012-11-08 ES ES12784857.0T patent/ES2635421T3/es active Active
- 2012-11-08 EP EP20193075.7A patent/EP3763370A1/en not_active Withdrawn
- 2012-11-08 US US13/672,475 patent/US20130123303A1/en not_active Abandoned
- 2012-11-09 TW TW108123351A patent/TW202014189A/zh unknown
- 2012-11-09 TW TW106103338A patent/TWI708604B/zh not_active IP Right Cessation
- 2012-11-09 TW TW101141967A patent/TWI580424B/zh active
- 2012-11-12 AR ARP120104260A patent/AR088845A1/es unknown
-
2014
- 2014-05-07 IL IL232483A patent/IL232483B/en active IP Right Grant
- 2014-05-12 CL CL2014001242A patent/CL2014001242A1/es unknown
- 2014-05-12 ZA ZA2014/03396A patent/ZA201403396B/en unknown
-
2015
- 2015-05-01 US US14/702,219 patent/US9308201B2/en active Active
- 2015-10-30 US US14/927,948 patent/US20160051534A1/en not_active Abandoned
-
2016
- 2016-08-17 AU AU2016216627A patent/AU2016216627B2/en not_active Ceased
- 2016-11-16 US US15/353,262 patent/US20170095466A1/en not_active Abandoned
-
2017
- 2017-05-08 JP JP2017092572A patent/JP6526737B2/ja active Active
-
2018
- 2018-08-21 IL IL261269A patent/IL261269A/en unknown
-
2019
- 2019-08-18 IL IL26875719A patent/IL268757A/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2014533271A5 (enExample) | ||
| JP6871400B2 (ja) | 眼表面疾患の治療のための製剤および関連方法 | |
| AU2008203101A1 (en) | Topical compositions comprising telmesteine for treating dermatological disorders | |
| JP2019534335A5 (enExample) | ||
| JP6526737B2 (ja) | ７−（１ｈ−イミダゾール−４−イルメチル）−５，６，７，８−テトラヒドロキノリンを含む肌の疾患および状態を治療するための医薬組成物 | |
| JP2017149767A5 (enExample) | ||
| US10201535B2 (en) | Pharmaceutical compositions comprising 7-(1H-imidazol-4-ylmethyl)-5,6,7,8-tetrahydro-quinoline for treating skin diseases and conditions | |
| RU2017111579A (ru) | Способы лечения и предотвращения заболеваний глаз, расстройств и патологических состояний меланином и аналогами, предшественниками и производными меланина | |
| RU2014106327A (ru) | Фармацевтические композиции, содержащие 4-бромо-n-(имидазолин-2-илиден)-1н-бензимидазол-5-амин для лечения кожных заболеваний | |
| JP2016501236A5 (enExample) | ||
| RU2011121659A (ru) | Депигментирующие местные композиции и их применение | |
| TW201637648A (zh) | 淚腺藥物遞輸系統 | |
| Young et al. | NS2, a novel aldehyde trap, decreases aldehyde levels in dry skin and eye models |